NGL Fine-Chem Limited (BOM:524774)

India · Delayed Price · Currency is INR

3,074.15

+30.95 (1.02%)

At close: Jun 19, 2026

206.48% (1Y)

Market Cap	18.99B +164.6%
Revenue (ttm)	5.01B +36.0%
Net Income	481.27M +127.8%
EPS	77.90 +127.8%
Shares Out	6.18M
PE Ratio	39.46
Forward PE	n/a
Dividend	1.75 (0.06%)
Ex-Dividend Date	Aug 18, 2026

Volume	655
Open	3,043.15
Previous Close	3,043.20
Day's Range	3,010.10 - 3,165.70
52-Week Range	985.05 - 3,200.00
Beta	0.63
Analysts	Strong Buy
Price Target	290.00 (-90.57%)
Earnings Date	Aug 5, 2026

About NGL Fine-Chem

NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for usage in veterinary and human health in India, Europe, the Asia Pacific, the United States, and internationally. The company offers animal health pharmaceutical ingredients, such as homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosphan, imidocarb dipropionate, triclabendazole, rafoxanide, diminazene aceturate, s-methoprene, carprofen, diminazene diaceturate, ractopamine HCI, toltra... [Read more]

Industry Medicinal Chemicals and Botanical Products

Founded 1981

Employees 520

Stock Exchange Bombay Stock Exchange

Ticker Symbol 524774

Full Company Profile

Financial Performance

In fiscal year 2026, NGL Fine-Chem's revenue was 5.01 billion, an increase of 36.03% compared to the previous year's 3.68 billion. Earnings were 481.27 million, an increase of 127.83%.

Financial Statements